Survival, GVHD, and duration of immunosuppression
| Outcome . | Treatment arm . | |||
|---|---|---|---|---|
| Etanercept, % (95% CI) . | Mycophenolate, % (95% CI) . | Denileukin, % (95% CI) . | Pentostatin, % (95% CI) . | |
| Overall survival* | ||||
| All patients | 47 (32-61) | 64 (48-76) | 49 (34-62) | 47 (31-62) |
| Excluding patients receiving MMF prophylaxis | 56 (37-71) | 64 (48-76) | 49 (30-65) | 52 (32-69) |
| GVHD-free survival at day 56 | 39 (25-53) | 71 (58-84) | 45 (31-59) | 55 (40-70) |
| Cumulative incidence† | ||||
| aGVHD flare at day 90 | 35 (21-49) | 27 (14-40) | 35 (21-49) | 36 (21-50) |
| Discontinuation of all immunosuppression | 35 (21-49) | 38 (24-52) | 21 (10-33) | 24 (11-37) |
| Chronic GVHD | 22 (10-34) | 47 (29-64) | 34 (20-48) | 30 (15-45) |
| Outcome . | Treatment arm . | |||
|---|---|---|---|---|
| Etanercept, % (95% CI) . | Mycophenolate, % (95% CI) . | Denileukin, % (95% CI) . | Pentostatin, % (95% CI) . | |
| Overall survival* | ||||
| All patients | 47 (32-61) | 64 (48-76) | 49 (34-62) | 47 (31-62) |
| Excluding patients receiving MMF prophylaxis | 56 (37-71) | 64 (48-76) | 49 (30-65) | 52 (32-69) |
| GVHD-free survival at day 56 | 39 (25-53) | 71 (58-84) | 45 (31-59) | 55 (40-70) |
| Cumulative incidence† | ||||
| aGVHD flare at day 90 | 35 (21-49) | 27 (14-40) | 35 (21-49) | 36 (21-50) |
| Discontinuation of all immunosuppression | 35 (21-49) | 38 (24-52) | 21 (10-33) | 24 (11-37) |
| Chronic GVHD | 22 (10-34) | 47 (29-64) | 34 (20-48) | 30 (15-45) |